4.20
price up icon3.70%   0.15
pre-market  Vorhandelsmarkt:  4.22   0.02   +0.48%
loading
Schlusskurs vom Vortag:
$4.05
Offen:
$4.08
24-Stunden-Volumen:
3.25M
Relative Volume:
0.61
Marktkapitalisierung:
$340.65M
Einnahmen:
$409.00K
Nettoeinkommen (Verlust:
$-101.35M
KGV:
-2.561
EPS:
-1.64
Netto-Cashflow:
$-71.49M
1W Leistung:
+0.48%
1M Leistung:
-40.26%
6M Leistung:
-39.48%
1J Leistung:
-34.07%
1-Tages-Spanne:
Value
$4.0601
$4.25
1-Wochen-Bereich:
Value
$3.93
$4.2765
52-Wochen-Spanne:
Value
$2.90
$11.16

Altimmune Inc Stock (ALT) Company Profile

Name
Firmenname
Altimmune Inc
Name
Telefon
(240) 654-1450
Name
Adresse
910 CLOPPER ROAD, GAITHERSBURG, MD
Name
Mitarbeiter
59
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-05
Name
Neueste SEC-Einreichungen
Name
ALT's Discussions on Twitter

Vergleichen Sie ALT mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
ALT
Altimmune Inc
4.20 339.03M 409.00K -101.35M -71.49M -1.64
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
470.13 119.21B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
560.93 59.16B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
325.28 40.57B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
571.23 34.02B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
295.59 29.19B 3.81B -644.79M -669.77M -6.24

Altimmune Inc Stock (ALT) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-07-10 Fortgesetzt Goldman Sell
2025-02-28 Eingeleitet William Blair Mkt Perform
2025-01-08 Eingeleitet Stifel Buy
2024-11-12 Eingeleitet UBS Buy
2024-04-29 Herabstufung Guggenheim Buy → Neutral
2024-01-24 Eingeleitet Goldman Neutral
2023-03-22 Herabstufung Goldman Buy → Neutral
2022-12-01 Eingeleitet Goldman Buy
2021-12-29 Fortgesetzt Jefferies Buy
2021-06-02 Eingeleitet H.C. Wainwright Buy
2021-02-11 Eingeleitet Guggenheim Buy
2020-12-14 Eingeleitet Jefferies Buy
2020-11-12 Bestätigt B. Riley Securities Buy
2020-09-25 Eingeleitet B. Riley FBR Buy
2020-08-14 Eingeleitet Evercore ISI Outperform
2020-07-31 Eingeleitet Piper Sandler Overweight
2020-07-28 Eingeleitet JMP Securities Mkt Outperform
2020-02-24 Fortgesetzt ROTH Capital Buy
2019-07-19 Eingeleitet ROTH Capital Buy
2017-10-09 Eingeleitet Piper Jaffray Overweight
Alle ansehen

Altimmune Inc Aktie (ALT) Neueste Nachrichten

pulisher
03:34 AM

Is Altimmune Inc. a good long term investmentPowerful growth strategies - Autocar Professional

03:34 AM
pulisher
12:06 PM

What drives Altimmune Inc. stock priceConsistent triple-digit returns - jammulinksnews.com

12:06 PM
pulisher
Jul 22, 2025

What analysts say about Altimmune Inc. stockPowerful growth strategies - Autocar Professional

Jul 22, 2025
pulisher
Jul 22, 2025

Shareholders Alert: Investigation Into Altimmune, Inc. (ALT)Contact Levi & Korsinsky to Protect Your Rights - ACCESS Newswire

Jul 22, 2025
pulisher
Jul 22, 2025

Why Altimmune Inc. stock attracts strong analyst attentionRisk Adjusted Stock Signals - Newser

Jul 22, 2025
pulisher
Jul 22, 2025

Lost Money on Altimmune, Inc. (ALT)? Contact Levi & Korsinsky About Fraud Investigation - ACCESS Newswire

Jul 22, 2025
pulisher
Jul 21, 2025

Altimmune Inc. Stock Analysis and ForecastFree High-Return Strategy Alerts - Autocar Professional

Jul 21, 2025
pulisher
Jul 21, 2025

Levi & Korsinsky Reminds Altimmune, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities LawsALT - ACCESS Newswire

Jul 21, 2025
pulisher
Jul 21, 2025

Investors in Altimmune, Inc. (ALT) Warned of Potential Securities FraudContact Levi & Korsinsky Today - Newsfile

Jul 21, 2025
pulisher
Jul 20, 2025

(ALT) Technical Pivots with Risk Controls - news.stocktradersdaily.com

Jul 20, 2025
pulisher
Jul 20, 2025

ALT ALERT: Ongoing Investigation Into Altimmune, Inc.Contact Levi & Korsinsky - ACCESS Newswire

Jul 20, 2025
pulisher
Jul 19, 2025

Securities Litigation as a Strategic Tool: Lessons from Altimmune's Legal Challenges and the Role of the Schall Law Firm - AInvest

Jul 19, 2025
pulisher
Jul 19, 2025

ALT Investors Have Opportunity to Join Altimmune, Inc. Fraud Investigation with the Schall Law Firm - Business Wire

Jul 19, 2025
pulisher
Jul 18, 2025

Did Altimmune, Inc. (ALT) Mislead Investors? Levi & Korsinsky Investigates - ACCESS Newswire

Jul 18, 2025
pulisher
Jul 17, 2025

Lost Investment in Altimmune, Inc. (ALT)? Levi & Korsinsky Launches Securities Fraud Investigation - ACCESS Newswire

Jul 17, 2025
pulisher
Jul 17, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc.ALT - WV News

Jul 17, 2025
pulisher
Jul 15, 2025

What makes Altimmune Inc. stock price move sharplyFree Smart Money Stock Analysis - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

How Altimmune Inc. stock performs during market volatilityTrending Stock Alert - Newser

Jul 15, 2025
pulisher
Jul 14, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Altimmune, Inc. - GlobeNewswire Inc.

Jul 14, 2025
pulisher
Jul 14, 2025

OneDigital Investment Advisors LLC Sells 2,887 Shares of Altimmune, Inc. (NASDAQ:ALT) - Defense World

Jul 14, 2025
pulisher
Jul 14, 2025

Concurrent Investment Advisors LLC Purchases New Holdings in Altimmune, Inc. (NASDAQ:ALT) - Defense World

Jul 14, 2025
pulisher
Jul 13, 2025

Altimmune (NASDAQ:ALT) Upgraded to “Strong Sell” at The Goldman Sachs Group - Defense World

Jul 13, 2025
pulisher
Jul 12, 2025

Altimmune (NASDAQ:ALT) Upgraded at The Goldman Sachs Group - Defense World

Jul 12, 2025
pulisher
Jul 12, 2025

Pomerantz LLP investigates securities fraud claims in Altimmune's IMPACT Phase 2b trial. - AInvest

Jul 12, 2025
pulisher
Jul 12, 2025

Altimmune (NASDAQ:ALT) Rating Increased to Strong Sell at The Goldman Sachs Group - Defense World

Jul 12, 2025
pulisher
Jul 12, 2025

The Goldman Sachs Group Upgrades Altimmune (NASDAQ:ALT) to Strong Sell - Defense World

Jul 12, 2025
pulisher
Jul 12, 2025

Altimmune (NASDAQ:ALT) Stock Rating Upgraded by The Goldman Sachs Group - Defense World

Jul 12, 2025
pulisher
Jul 12, 2025

JMP Securities Lowers Altimmune (NASDAQ:ALT) Price Target to $15.00 - Defense World

Jul 12, 2025
pulisher
Jul 11, 2025

Altimmune’s RESTORE TRIAL: A Promising Step in ALD Treatment - TipRanks

Jul 11, 2025
pulisher
Jul 10, 2025

Altimmune falls after Goldman resumes coverage with "sell", citing competition - TradingView

Jul 10, 2025
pulisher
Jul 10, 2025

Citizens JMP lowers Altimmune stock price target to $15 on fibrosis miss - Investing.com Nigeria

Jul 10, 2025
pulisher
Jul 10, 2025

Goldman Sachs downgrades Altimmune stock to Sell on pemvidutide concerns - Investing.com Canada

Jul 10, 2025
pulisher
Jul 10, 2025

Altimmune Plunges 14.56% on Goldman Sachs Downgrade - AInvest

Jul 10, 2025
pulisher
Jul 10, 2025

Altimmune resumed with a Sell at Goldman Sachs - TipRanks

Jul 10, 2025
pulisher
Jul 10, 2025

Sell Rating for Altimmune Inc. Due to Financial Struggles and Competitive Challenges in Drug Development - TipRanks

Jul 10, 2025
pulisher
Jul 10, 2025

Altimmune enrolls first patient in ALD treatment trial By Investing.com - Investing.com South Africa

Jul 10, 2025
pulisher
Jul 10, 2025

ATTENTION Altimmune, Inc. (ALT) Investors: Possible FraudContact Levi & Korsinsky Today - ACCESS Newswire

Jul 10, 2025
pulisher
Jul 09, 2025

How To Trade (ALT) - news.stocktradersdaily.com

Jul 09, 2025
pulisher
Jul 09, 2025

Levi & Korsinsky Launches Fraud Investigation on Behalf of Altimmune, Inc. (ALT) Shareholders - ACCESS Newswire

Jul 09, 2025

Finanzdaten der Altimmune Inc-Aktie (ALT)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$21.80
price up icon 0.51%
$36.10
price up icon 1.26%
$102.92
price up icon 0.14%
$26.54
price up icon 0.76%
$111.44
price up icon 2.32%
biotechnology ONC
$295.59
price up icon 1.25%
Kapitalisierung:     |  Volumen (24h):